Article Correctness Is Author's Responsibility: UNM Cancer Center Plays Key Role in First-in- Human Testing of New Cancer Drug

The UNM Comprehensive Cancer Center played a key role in the first clinical trials of a new drug that targets solid cancer tumors. The Phase 1A clinical trials mark the first time ever the drug, called BXQ-350, was used in people. BXQ-350 is comprised of a human protein called SapC and a human lipid called DOPS.
Posted in Uncategorized